ArticlesLong-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial
Introduction
Bronchiectasis and chronic suppurative lung disease, which we collectively term bronchiectasis, unrelated to cystic fibrosis, is characterised by recurrent bacterial infection and airway inflammation.1, 2 Its prevalence is especially high in Indigenous children from high-income countries such as Australia, New Zealand, and the USA, ranging from 63 to 1600 per 100 000 children.2 Treatment of bronchiectasis aims to resolve acute infection and control infection and inflammation. Treatment improves symptoms (persistent or recurrent wet cough and breathlessness), reduces frequency of acute pulmonary exacerbations, preserves lung function, and improves quality of life.1 Pulmonary exacerbations (especially those needing admission to hospital) are the only known independent risk factor for long-term pulmonary decline in children with bronchiectasis.3 The public health importance of bronchiectasis is shown by Indigenous Australians dying from bronchiectasis in the third and fourth decades of life.4 This poor outcome might be the result of scarce access to medical care and delayed or inadequate treatment early in life, since lung function is stable when children are managed optimally.4
Because bacteria have a central role in pathogenesis,5 antibiotics are used to reduce bacterial load and accompanying airway inflammation.1, 6 Antibiotics are administered regularly for treatment of exacerbations;1, 6 however, their use as maintenance therapy over prolonged periods is controversial. Although long-term antibiotics might reduce exacerbations, the absence of high-quality evidence in children (and concerns about antibiotic resistance) means they are not recommended as routine treatment.1 Moreover, evidence is also scarce for Indigenous populations, who are among the most disadvantaged groups in affluent countries and for whom optimum management of disease is often most difficult to achieve.
In children with cystic fibrosis, 6 months of treatment with azithromycin leads to modest improvement in lung function, reduced pulmonary exacerbation rates, and improved weight gain.7 Its antimicrobial effects, anti-inflammatory actions, and prolonged half-life (allowing once-weekly oral dosing)8 make azithromycin an attractive option for maintenance treatment. Randomised controlled trials in adults with bronchiectasis showed that 6 months and 12 months of azithromycin reduced rates of pulmonary exacerbation and respiratory symptoms.9, 10 By contrast, there are no reported randomised controlled trials of long-term antibiotics in children with bronchiectasis, even though infective exacerbations in developing lungs could lead to substantial impairment of lung function in adulthood.11
Our study (the Bronchiectasis Intervention Study) aimed to establish whether long-term (24 months) antibiotic treatment with azithromycin would reduce the rate of pulmonary exacerbations in Indigenous children with non-cystic-fibrosis bronchiectasis. We also monitored for serious adverse events associated with azithromycin and examined its effect on nasopharyngeal carriage of bacterial pathogens.12
Section snippets
Study design and participants
We did this multicentre, double-blind, randomised, parallel-group, placebo-controlled trial in Australia and New Zealand. Details of this study were described previously.13 Briefly, between Nov 12, 2008, and Dec 23, 2010, we enrolled Indigenous children from community clinics in central and northern Australia, and urban Maori and Pacific Island children from a tertiary paediatric hospital in Auckland (New Zealand) who were aged 1–8 years, lived within the study area, had either bronchiectasis
Results
Of 92 eligible children, 89 were enrolled, 45 were randomised to receive azithromycin and 44 placebo (figure 1). Of children enrolled, 75 (84%) received the intervention for 12 months or more (52 children [58%] received the intervention for 23–24 months [26 in each group] and 11 children [12%] for 18–22 months [four in the placebo group and seven in the azithromycin group]). Table 115 shows baseline characteristics. The most substantial difference was mechanical ventilation with more children
Discussion
We showed that once-weekly azithromycin administered for 12–24 months to Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease significantly reduced pulmonary exacerbations and improved weight-for-age Z-scores. Additionally, post-hoc analysis showed that children given azithromycin had significantly fewer non-pulmonary illnesses treated acutely with non-macrolide antibiotics. The study drug was well tolerated with no trial-medication-related differences
References (44)
- et al.
Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: what influences lung function stability?
Chest
(2010) - et al.
Bronchiectasis in Central Australia: a young face to an old disease
Respir Med
(2008) Airway microbiology and host defences in paediatric non-CF bronchiectasis
Paediatr Respir Rev
(2011)- et al.
Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial
Lancet
(2012) - et al.
Lung development and adult lung diseases
Chest
(2007) - et al.
Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis
J Pediatr
(2010) - et al.
A multi-method assessment of treatment adherence for children with cystic fibrosis
J Cyst Fibros
(2006) - et al.
Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis
Respir Med
(2008) Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases
Lancet Respir Med
(2013)- et al.
Skin disorders, including pyoderma, scabies, and tinea infections
Pediatr Clin North Am
(2009)
Indigenous health in Australia, New Zealand, and the Pacific
Lancet
Diagnosing and preventing chronic suppurative lung disease (CSLD) and bronchiectasis
Paediatr Respir Rev
Differences and similarities in non-cystic fibrosis bronchiectasis between developing and affluent countries
Paediatr Respir Rev
Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand
Med J Aust
Emerging drugs for bronchiectasis
Expert Opin Emerg Drugs
Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis
Am J Respir Crit Care Med
Macrolide antibiotics for cystic fibrosis
Cochrane Database Syst Rev
The role of macrolides in childhood non-cystic fibrosis-related bronchiectasis
Mediators Inflamm
Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial
JAMA
Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial
BMC Pediatr
Management of bronchiectasis and chronic suppurative lung disease in indigenous children and adults from rural and remote Australian communities
Med J Aust
Assessment of airway neutrophils by sputum colour: correlation with airways inflammation
Thorax
Cited by (143)
A core outcome set for bronchiectasis in children and adolescents for use in clinical research: an international consensus study
2024, The Lancet Respiratory MedicineLong-term Azithromycin in Children With Bronchiectasis Unrelated to Cystic Fibrosis: Treatment Effects Over Time
2023, ChestCitation Excerpt :Although our models adjusted for country of enrollment (Table 5), there was likely residual confounding related to sociocultural or genetic differences.36 However, we can only speculate about the potential residual confounding because these factors were not collected in our study.6 Alternatively, obesity is associated with lung diseases, including severe bronchiectasis.37
Bronchiectasis in Childhood
2022, Clinics in Chest MedicineDisease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease
2024, Arthritis Care and ResearchNon-CF Bronchiectasis
2024, Progress in Inflammation Research